Adaptimmune Therapeutics Stock Forecast

ADAP's stock price has decreased by -76.44% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 5 analysts with 12-month price forecasts for Adaptimmune Therapeutics stock have an average target of 1.83, with a low estimate of 1.40 and a high estimate of 3.00. The average target predicts an increase of 654.02% from the current stock price of 0.24.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$1.40	$1.83	$1.50	$3.00
Change	+476.84%	+654.02%	+518.05%	+1136.1%

Analyst Ratings

The average analyst rating for Adaptimmune Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25	Apr '25
Strong Buy	2	2	2	2	2	2
Buy	2	2	2	2	2	2
Hold	0	0	0	0	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Arthur He HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $3.5 → $3	Strong Buy	Maintains	$3.5 → $3	+1,136.09%	Apr 1, 2025
Michael Schmidt Guggenheim	Guggenheim	Strong Buy Maintains $3 → $1.75	Strong Buy	Maintains	$3 → $1.75	+621.05%	Mar 26, 2025
Yanan Zhu Wells Fargo	Wells Fargo	Hold Maintains $2 → $1.5	Hold	Maintains	$2 → $1.5	+518.05%	Mar 21, 2025
George Farmer Scotiabank	Scotiabank	Buy Maintains $3.15 → $1.4	Buy	Maintains	$3.15 → $1.4	+476.84%	Mar 21, 2025
Graig Suvannavejh Mizuho	Mizuho	Buy Maintains $3 → $1.5	Buy	Maintains	$3 → $1.5	+518.05%	Nov 27, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

42.44M

from 178.03M

-76.16%

from 178.03M

Revenue Next Year

70.24M

from 42.44M

65.49%

from 42.44M

EPS This Year

-0.40

from -0.30

EPS Next Year

-0.36

from -0.40

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	3.96M	6.15M	27.15M	60.28M	178.03M	42.44M	70.24M	130.40M
Revenue Growth	252.76%	55.36%	341.50%	122.05%	195.34%	-76.16%	65.49%	85.66%
EPS	-0.91	-1.02	-1.03	-0.57	-0.30	-0.40	-0.36	-0.35
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	8	6	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	63.8M	89.8M	157.7M
Avg	42.4M	70.2M	130.4M
Low	29.5M	49.3M	103.9M

Revenue Growth

Revenue Growth	2025	2026	2027
High	-64.1%	111.5%	124.6%
Avg	-76.2%	65.5%	85.7%
Low	-83.4%	16.2%	48.0%

EPS Forecast

EPS	2025	2026	2027
High	-0.11	-0.06	-0.36
Avg	-0.40	-0.36	-0.35
Low	-0.54	-0.49	-0.35

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.